Skip to main content
. 2020 Jul 27;7(3):639–648. doi: 10.1007/s40744-020-00222-7

Table 1.

Subject demographic and clinical characteristics

Patient Gender Age (years) BMI (kg/m2) Pre-therapy sUA (mg/dl) SubQ tophi eGFRa (ml/min/1.73 m2) Comorbidities
1 Male 77 28.2 9.6 Yes 37 HTN, CKD, CAD, DM, DL, lower lid mass
2 Male 61 27.9 9.0 Yes 91 DM, DL, OA, bipolar disorder
3 Male 45 32.1 8.0 Yes 111 HTN, anxiety
4 Male 64 26.9 5.7 Yes 59 CKD
5 Male 57 25.2 8.1 Yes 60 OA
6 Male 55 30.0 11.6 Yes 74 HTN, CKD, DM, OA, DN, history of AKI
7 Male 29 22.9 9.5 Yes 106 HTN, anxiety, polyarthralgia
8 Female 40 31.5 13.1 Yes 84 HTN, rheumatoid arthritis
9 Male 49 30.2 10.6 Yes 76 HTN, OA, kidney stone
10 Male 46 29.0 9.0 Yes 86 HTN, OA, chondrocalcinosis (wrist)
Mean ± SD 52.3 ± 13.5 28.4 ± 2.8 9.42 ± 2.05 10 (100%) 78.4 ± 22.5

sUA serum uric acid levels; SubQ subcutaneous; eGFR estimated glomerular filtration rate; SD standard deviation; HTN hypertension; CAD coronary artery disease; DM diabetes mellitus; DL dyslipidemia; OA osteoarthritis; CKD chronic kidney disease; DN diabetic neuropathy; AKI acute kidney injury

aCalculated using serum creatinine levels using the abbreviated MDRD equation [23]